Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2012

01-08-2012 | Original Article

Development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of epidermal growth factor receptor

Authors: Dimitrios Konstantinos Papageorgiou, Theocharis Konsatntinidis, Nektaria Skandalaki, Anna Papadouri, Theodora Pappa, Stavroula Poulopoulou

Published in: Supportive Care in Cancer | Issue 8/2012

Login to get access

Abstract

Purpose

The aim of this study was the development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of EGFR (intravenous regimens).

Methods

Five nurses with experience in oncology created a 25-item questionnaire. The questionnaire was presented to six experts for assessment of face and content validity. Item analysis and reliability testing were evaluated on the test results of 76 nurses.

Results

Face and content validity was achieved for 25 items. Two items with low biserial correlations were deleted. The values for item difficulty range from 0.2 to 0.7. The values for item discrimination ranged from 0.25 to 0.64. The complete post-tested 23-item questionnaire showed excellent internal consistency with Kuder–Richardson 20 score of 0.909. The Cohen κ tests showed that the questionnaire has very good test–retest reliability. The specific tool can be used in several studies, leading to the development of educational interventions.
Literature
1.
Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12:5268PubMedCrossRef
2.
Giadiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 11(6):755–768CrossRef
3.
Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15 (Review)PubMedCrossRef
4.
Wainberg Z, Hecht JR (2006) Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther 6(11):1229–1235PubMedCrossRef
5.
Ng M, Cunningham D (2004) Cetuximab (Erbitux)—an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int J Clin Pract 58(10):970–976PubMedCrossRef
6.
Bernier J et al (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19(1):142–149PubMedCrossRef
7.
8.
Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201–1208PubMedCrossRef
9.
Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ (2009) Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 27(11):1822–1828PubMedCrossRef
10.
11.
Haladyna TM (1999) Developing and validating multiple-choice test items. Lawrence Erlbaum, Hillsdale
12.
Wiersma W, Jurs SG (1990) Educational measurement and testing. Allyn & Bacon, Boston
Metadata
Title
Development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of epidermal growth factor receptor
Authors
Dimitrios Konstantinos Papageorgiou
Theocharis Konsatntinidis
Nektaria Skandalaki
Anna Papadouri
Theodora Pappa
Stavroula Poulopoulou
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 8/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1257-y

Other articles of this Issue 8/2012

Supportive Care in Cancer 8/2012 Go to the issue

Original Article

The Psychosocial Distress Questionnaire-Breast Cancer (PDQ-BC) is a useful instrument to screen psychosocial problems

Original Article

Racial disparities in physical and functional domains in women with breast cancer

Original Article

Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer

Original Article

Prospective assessment of health-related quality of life in patients with low-grade glioma

Original Article

Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids

Original Article

Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002–2008
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits